Secondary prevention of cardiovascular disease, including cholesterol targets: summary of updated NICE guidance

BMJ. 2024 Mar 28:384:q637. doi: 10.1136/bmj.q637.

Authors

David Wonderling¹, Alfredo Mariani², Eleanor J Samarasekera², Colin Wilkinson³, Riyaz S Patel^{4

5}, Joseph Mills⁶; Guideline Committee

Collaborators

Guideline Committee:
Nigel Beckett, Beverley Bostock, Chris Clark, Hugh Gallagher, Mark Glover, Satwinder Kaur, Paul Leeson, Joseph Mills, Riyaz Patel, David Preiss, Ruth Price, Sharon Seber, Eduard Shantsila, Wayne Sunman, Colin Wilkinson, Parijat De, Aroon Hingorani, Judith Magowan, Chakravarthi Rajkumar

Affiliations

¹ National Institute for Health and Care Excellence, London, UK David.Wonderling@nice.org.uk.
² National Institute for Health and Care Excellence, London, UK.
³ Public representative.
⁴ Institute of Cardiovascular Science, University College London, London.
⁵ Barts Heart Centre, St Bartholomew's Hospital, London.
⁶ Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool.

PMID: 38548279
DOI: 10.1136/bmj.q637

No abstract available

MeSH terms

Cardiovascular Diseases* / prevention & control
Cholesterol
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Secondary Prevention

Substances

Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors